Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | HAS2 |
| Gene Name: | HAS2 |
| Protein Full Name: | Hyaluronan synthase 2 |
| Alias: | EC 2.4.1.212; HA synthase 2; Hyaluronic acid synthase 2 |
| Mass (Da): | 63566 |
| Number AA: | 552 |
| UniProt ID: | Q92819 |
| Locus ID: | 3037 |
| COSMIC ID: | HAS2 |
| Gene location on chromosome: | 8q24.13; 8q24.12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19723 |
| Percent of cancer specimens with mutations: | 0.71 |
| Deregulated in translocations: | Lipoblastomas. Fusion partner is PLAG1. |
| Normal role description: | HAS2 is a transmembrane protein of the glycosyl transferase family which catalyzes the polymerization of hyaluronic acid (HA) chains. HA functions as a component of the extracellular matrix and contributes to cell proliferation and migration especially during wound healing and regulating inflammation. HAS2 may have a role in promoting cancer metastasis through increased HA production. Metastatic tumours expressing high levels of HAS and HA can can bind the HA receptor, CD44 or RHAMM, leading to epithelial-mesenchymal transition of the cancer. Overexpression of HAS2 has been observed in various metastatic cancers and HA expression has been used as a diagnostic test for malignant cancers. |